BIOAFFINITY TECHNOLOGIES, INC.

NASDAQ: BIAF (bioAffinity Technologies, Inc.)

Last update: 24 Jun, 7:38PM

0.248

0.02 (7.73%)

Previous Close 0.230
Open 0.240
Volume 712,831
Avg. Volume (3M) 12,756,064
Market Cap 7,057,956
Price / Sales 0.590
Price / Book 7.90
52 Weeks Range
0.164 (-33%) — 2.99 (1105%)
Earnings Date 12 Aug 2025 - 18 Aug 2025
Profit Margin -110.55%
Operating Margin (TTM) -141.73%
Diluted EPS (TTM) -0.710
Quarterly Revenue Growth (YOY) -23.00%
Total Debt/Equity (MRQ) 92.48%
Current Ratio (MRQ) 0.550
Operating Cash Flow (TTM) -6.56 M
Levered Free Cash Flow (TTM) -2.98 M
Return on Assets (TTM) -88.58%
Return on Equity (TTM) -290.85%

Market Trend

Short Term Medium Term
Industry Diagnostics & Research (US) Mixed Mixed
Diagnostics & Research (Global) Mixed Mixed
Stock bioAffinity Technologies, Inc. Mixed -

AIStockmoo Score

-0.5
Analyst Consensus NA
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 2.5
Technical Oscillators -2.0
Average -0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
BIAF 7 M - - 7.90
SHC 5 B - 180.89 9.02
TWST 2 B - - 3.42
NEOG 1 B - - 0.570
CDNA 690 M - 12.35 2.31
CSTL 553 M - - 1.36

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company’s product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Sector Healthcare
Industry Diagnostics & Research
Investment Style Small Core
% Held by Insiders 24.53%
% Held by Institutions 1.80%

No data within this time range.

No data within this time range.

Date Type Details
17 Sep 2025 Announcement bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
09 Sep 2025 Announcement Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
03 Sep 2025 Announcement U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
18 Aug 2025 Announcement bioAffinity Technologies Appoints New Members to Board of Directors
14 Aug 2025 Announcement bioAffinity Technologies Reports Second Quarter 2025 Results
13 Aug 2025 Announcement WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
13 Aug 2025 Announcement bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
13 Aug 2025 Announcement bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
29 Jul 2025 Announcement Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
23 Jul 2025 Announcement Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
22 Jul 2025 Announcement Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
15 Jul 2025 Announcement bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
09 Jul 2025 Announcement Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
26 Jun 2025 Announcement bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
24 Jun 2025 Announcement bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria